U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H12ClNO2
Molecular Weight 273.714
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARPROFEN

SMILES

CC(C(O)=O)C1=CC2=C(C=C1)C3=C(N2)C=CC(Cl)=C3

InChI

InChIKey=PUXBGTOOZJQSKH-UHFFFAOYSA-N
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C15H12ClNO2
Molecular Weight 273.714
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Carprofen is an anti-inflammatory drug developed in Japan by Nippon Roche Research Center. Carprofen, as many NSAIDs, selectively inhibits COX-2 and was shown to suppress inflammation in vitro, using osteoarthritis models. The drug was approved by FDA for human use under the name Ridamyl, however, now it is sold only for veterinary purposes and prescribed for the treatment of postoperative pain and the relief of pain and inflammation associated with osteoarthritis in dogs.

Originator

Curator's Comment: The full version can be found here: https://www.jstage.jst.go.jp/article/fpj1944/73/7/73_7_757/_pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.102 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
RIMADYL

Approved Use

Rimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Launch Date

1996
Primary
RIMADYL

Approved Use

Rimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.2 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.4 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
52.4 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
57.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARPROFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

The recommended dosage for oral administration to dogs is 2 mg/lb (4.4 mg/kg) of body weight daily. The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb (2.2 mg/kg) twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure.
Route of Administration: Oral
Canine chondrocytes isolated from normal canine articular cartilage were used to create an in vitro model of osteoarthritis. Cells were incubated at 37C in a 5% CO2 atmosphere for 72 h and then treated with 500 uL of the pro-inflammatory cytokine, interleukin-1b (IL-1b) (10 ng/mL in serum-free medium) to induce inflammatory conditions and incubated at 37C in 5% CO2 atmosphere for 2 h. Carprofen was added to the cells at concentration from 0.1 to 250 ug/mL.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:18:28 GMT 2023
Edited
by admin
on Sat Dec 16 17:18:28 GMT 2023
Record UNII
FFL0D546HO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARPROFEN
GREEN BOOK   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CARPROFEN [USP MONOGRAPH]
Common Name English
RO-20-5720/000
Code English
CARPROFEN [GREEN BOOK]
Common Name English
CARPROFEN [MI]
Common Name English
(±)-6-CHLORO-.ALPHA.-METHYLCARBAZOLE-2-ACETIC ACID
Systematic Name English
CARPROFEN [MART.]
Common Name English
9H-CARBAZOLE-2-ACETIC ACID, 6-CHLORO-.ALPHA.-METHYL, (±)-
Common Name English
RO 20-5720/000
Code English
Carprofen [WHO-DD]
Common Name English
carprofen [INN]
Common Name English
RIMADYL
Brand Name English
CARPROFEN [ORANGE BOOK]
Common Name English
CARPROFEN [USP IMPURITY]
Common Name English
CARPROFEN FOR VETERINARY USE
EP  
Common Name English
CARPROFEN FOR VETERINARY USE [EP MONOGRAPH]
Common Name English
CARPROFEN [USAN]
Common Name English
CARPROFEN [USP-RS]
Common Name English
CARPROFEN [VANDF]
Common Name English
NSC-297935
Code English
Classification Tree Code System Code
CFR 21 CFR 520.304
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
NCI_THESAURUS C257
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
WHO-VATC QM01AE91
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
CFR 21 CFR 522.304
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C65290
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
DRUG BANK
DB00821
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
INN
3980
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
PUBCHEM
2581
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
DRUG CENTRAL
518
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
CAS
53716-49-7
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
MERCK INDEX
m3132
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY Merck Index
RXCUI
20343
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
258-712-4
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
DAILYMED
FFL0D546HO
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
MESH
C007005
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
RS_ITEM_NUM
1096699
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
CHEBI
364453
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
EVMPD
SUB06144MIG
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
SMS_ID
100000081327
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
FDA UNII
FFL0D546HO
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
NSC
297935
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
IUPHAR
7141
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL1316
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
WIKIPEDIA
CARPROFEN
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045871
Created by admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY